Qiagen said it is working with Nvidia to integrate accelerated computing and Nvidia BioNeMo into its Qiagen Digital Insights curated biomedical knowledgebases. The company said the goal is to expand how AI is used to interpret disease biology, identify therapeutic targets, and develop biomarkers. The partnership centers on Qiagen’s Discovery Platform and uses graph-based AI to connect evidence across genes, diseases, pathways, compounds, and clinical insights. Qiagen plans to offer initial pilot programs to select biopharma and biotech partners, with broader availability after validation. The announcement signals continued commercialization of AI-driven “knowledge graph” approaches, moving beyond single-model analytics toward multi-step and agentic workflows in drug discovery and development decision-making.